(Q39231255)

10 September 2017

1 reference

title

Advances in therapy for childhood non-B-lymphoblastic leukaemia (English)

1 reference

10 September 2017

1 reference

Rivera GK

1

1 reference

10 September 2017

publication date

1 June 1994

1 reference

Best Practice and Research: Clinical Haematology

10 September 2017

published in

1 reference

10 September 2017

volume

7

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

273-298

1 reference

[Acute lymphoblastic leukemia in infancy: results of 5 multicenter ALL-BFM therapy studies 1970-1986]

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Which treatment for childhood acute lymphoblastic leukaemia in second remission?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Clinical implications of cytogenetic and molecular analyses of pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Immunotoxins: a clinical review of their use in the treatment of malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

The cytogenetics of childhood leukemia: clinical and biologic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Discontinuing therapy in childhood acute lymphocytic leukemia. A multicentric survey in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Cessation of therapy in childhood leukemia. A survey of 160 cases from the Nordic Countries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Late effects of antileukemic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Phase I-II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Progress in the treatment of adolescents with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

The epipodophyllotoxins: both sides of the coin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

Non-Hodgkin's lymphoma in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980203-3

7 January 2021

10.1016/S0950-3536(05)80203-3

Identifiers

DOI

1 reference

10 September 2017

1 reference